English
Home > Products > Delamanid advance intermediate

China Delamanid advance intermediate Factory

Assume full accountability to meet all requires of our purchasers; realize continual advancements by selling the advancement of our customers; grow to be the final permanent cooperative partner of consumers and maximize the interests of clientele for Delamanid advance intermediate,CAS NO 681482-81-5,681482-81-5,Delamanid intermediate,4-[4-[4-(trifluoroMethoxy)phenoxy]piperidin-1-yl]phenol, Never-ending improvement and striving for 0% deficiency are our two main quality policies. Should you need anything, don't hesitate to contact us.
Delamanid advance intermediate, we rely on own advantages to build a mutual-benefit commerce mechanism with our cooperative partners. As a result, we've gained a global sales network reaching the Middle East, Turkey, Malaysia and Vietnamese.

Related Products

Hot Products

  • Nomegestrol

    Nomegestrol

    Product Name:Nomegestrol
    Molecular Formula:C21H28O3
    Molecular Weight:328.45
    CAS Registry Number;58691-88-6
  • Esomeprazole

    Esomeprazole

    Product Name:Esomeprazole
    Molecular Formula:C17H19N3O3S
    Molecular Weight;345.42
    CAS Registry Number;119141-88-7
  • 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid

    2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid

    Product Name:2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid
    Molecular Formula:C24H23F2N3O6S
    Molecular Weight:519.52
    CAS Registry Number:1589503-95-6
  • PeraMpanel

    PeraMpanel

    Product Name:PeraMpanel
    Molecular Formula:C23H15N3O
    Molecular Weight;349.38
    CAS Registry Number;380917-97-5
  • Estriol

    Estriol

    Product Name:Estriol
    Molecular Formula:C18H24O3
    Molecular Weight:288.38
    CAS Registry Number;50-27-1
  • 2-Fluoro-6-trifluoromethylpyridine

    2-Fluoro-6-trifluoromethylpyridine

    Product Name:2-Fluoro-6-trifluoromethylpyridine
    Molecular Formula:C6H3F4N
    Molecular Weight:165.09
    CAS Registry Number:94239-04-0
  • Related Blog
  • Reviews

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • How much do you know about minocycline hydrochloride?

    Minocycline hydrochloride is commonly used as its hydrochloride, which is yellow crystalline powder, odorless, bitter in taste, and can cause deterioration when exposed to light. Soluble in water, slightly soluble in ethanol, easily soluble in alkali metal hydroxide or carbonate solution.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept